EGFR and non-small cell lung carcinoma: Recently, Zhang et al. identified ACK1 activation as a novel mechanism resisting EGFR inhibitor ASK120067 in NSCLC and concurrently inhibiting EGFR and ACK1 could overcome the acquired resistance of ASK120067 efficaciously (Zhang et al. 2020).